FRC-222
FRC-222 is a CHD1 tandem chromodomain inhibitor with a Kd of 0.15 μM and an IC50 of 0.18 μM. FRC-222 binds to the H3K4me3 binding site of CHD1 tandem chromodomain via aromatic cage interactions and extended ligand contacts. FRC-222 can be used for the research of prostate cancer[1].
Para uso exclusivo en investigación. No vendemos a pacientes.
- Fòrmula: C36H45N5O2
- Peso molecular:579.77
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Ver todos los productos específicos de isoformas DNA/RNA Synthesis
More
Actividad biológica
FRC-222 (Compound 2n) binds to purified recombinant CHD1 tandem chromodomain with a Kd of 0.15 μM[1].
FRC-222 inhibits the interaction between purified recombinant CHD1 tandem chromodomain and H3K4me3 peptide with an IC50 of 0.49 μM[1].
FRC-222 (25-100 μM) engages endogenous full-length CHD1 in HEK293T cell lysate, competitively inhibiting its binding to LSD1-K114me3 peptide in a concentration-dependent manner[1].
FRC-222 (10 μM) shows high selectivity against purified LSD1, KMT9, METTL21A, EHMT2 (G9a), SET8, and NSD2 enzymes, with minimal inhibition of DNMT1[1].
FRC-222 (16 μM) shows high selectivity against purified TAF3, SPIN1, and PHF8 methyl-lysine reader domains, with no significant inhibition of H3K4me3 peptide binding[1].
FRC-222 (0.8-6 μM; 48 h) impairs the viability of PC-3M-Luc prostate cancer cells in a concentration-dependent manner, with significant inhibition observed at concentrations ≥1.8 μM[1].
FRC-222 (0.8-6 μM; 48 h) potently impairs the viability of 22Rv1 prostate cancer cells in a concentration-dependent manner, with significant inhibition observed at concentrations ≥1.8 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:PC-3M-Luc prostate cancer cells
-
Concentration:0.8 μM; 1.2 μM; 1.8 μM; 2.7 μM; 4 μM; 6 μM
-
Incubation Time:48 h
-
Result:Retained over 110% of control cell viability at 0.8 μM and 1.2 μM.
Reduced viability to 60% of control at 1.8 μM.
Reduced viability to 35% of control at 2.7 μM.
Reduced viability to 25% of control at 4 μM.
Reduced viability to ~5% of control at 6 μM.
-
Cell Line:22Rv1 prostate cancer cells
-
Concentration:0.8 μM; 1.2 μM; 1.8 μM; 2.7 μM; 4 μM; 6 μM
-
Incubation Time:48 h
-
Result:Retained over 110% of control cell viability at 0.8 μM.
Retained ~90% of control viability at 1.2 μM.
Reduced viability to ~10% of control at 1.8 μM.
Reduced viability to ≤10% of control at concentrations ≥2.7 μM.
Chemical Information
-
Peso molecular 579.77
-
Fòrmula C36H45N5O2
-
SMILES
COC1=CC=C(C=C1)CNC2CCN(C3=NC4=CC(OCC)=CC=C4C(NC5CCN(CC6=CC=CC=C6)CC5)=C3)CC2
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
FRC-222 Related Classifications
HY-183603 Related Classifications
Powered by Bioz